136.18
-1.19 (-0.87%)
| Penutupan Terdahulu | 137.37 |
| Buka | 138.16 |
| Jumlah Dagangan | 937,679 |
| Purata Dagangan (3B) | 1,106,150 |
| Modal Pasaran | 13,577,920,512 |
| Harga / Pendapatan (P/E TTM) | 32.50 |
| Harga / Pendapatan (P/E Ke hadapan) | 19.05 |
| Harga / Jualan (P/S) | 5.19 |
| Harga / Buku (P/B) | 4.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Feb 2026 |
| Margin Keuntungan | 12.68% |
| Margin Operasi (TTM) | 4.14% |
| EPS Cair (TTM) | 2.95 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 11.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -81.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 19.45% |
| Nisbah Semasa (MRQ) | 3.13 |
| Aliran Tunai Operasi (OCF TTM) | 529.90 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 235.48 M |
| Pulangan Atas Aset (ROA TTM) | 8.75% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Menaik | |
| Stok | Neurocrine Biosciences, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.50 |
|
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 1.06% |
| % Dimiliki oleh Institusi | 98.86% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 203.00 (Citigroup, 49.07%) | Beli |
| Median | 179.00 (31.44%) | |
| Rendah | 164.00 (Canaccord Genuity, 20.43%) | Beli |
| Purata | 182.31 (33.87%) | |
| Jumlah | 11 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 142.45 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| UBS | 23 Jan 2026 | 178.00 (30.71%) | Beli | 136.18 |
| JP Morgan | 12 Jan 2026 | 177.00 (29.98%) | Beli | 132.66 |
| 03 Nov 2025 | 179.00 (31.44%) | Beli | 141.96 | |
| Morgan Stanley | 08 Jan 2026 | 175.00 (28.51%) | Pegang | 135.57 |
| 11 Nov 2025 | 173.00 (27.04%) | Beli | 147.29 | |
| Truist Securities | 08 Jan 2026 | 169.00 (24.10%) | Beli | 135.57 |
| 30 Oct 2025 | 172.00 (26.30%) | Beli | 138.04 | |
| HC Wainwright & Co. | 17 Dec 2025 | 198.00 (45.40%) | Beli | 141.70 |
| Mizuho | 12 Dec 2025 | 175.00 (28.51%) | Pegang | 152.80 |
| Stifel | 11 Dec 2025 | 188.00 (38.05%) | Beli | 154.75 |
| 29 Oct 2025 | 183.00 (34.38%) | Beli | 138.02 | |
| RBC Capital | 08 Dec 2025 | 180.00 (32.18%) | Beli | 154.99 |
| 29 Oct 2025 | 160.00 (17.49%) | Beli | 138.02 | |
| TD Cowen | 05 Dec 2025 | 200.00 (46.86%) | Beli | 155.51 |
| Canaccord Genuity | 29 Oct 2025 | 164.00 (20.43%) | Beli | 138.02 |
| Citigroup | 29 Oct 2025 | 203.00 (49.07%) | Beli | 138.02 |
| Needham | 29 Oct 2025 | 184.00 (35.12%) | Beli | 138.02 |
| Piper Sandler | 29 Oct 2025 | 179.00 (31.44%) | Beli | 138.02 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |